Together, IGF2BP3 could be a biomarker for prognosis and diagnosis of RCC, and knockdown of IGF2BP3 inhibited the proliferation, invasion, and metastasis of RCC. This evidence concerns the gene IGF2BP3 and renal cell carcinoma.